These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 32158560)

  • 1. PPAR
    Ma Y; Shi M; Wang Y; Liu J
    Int J Nephrol; 2020; 2020():2917474. PubMed ID: 32158560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The role of PPARgamma agonists in kidney diseases].
    Yokoyama Y; Doi S; Kawai T; Yorioka N
    Nihon Rinsho; 2010 Feb; 68(2):317-22. PubMed ID: 20158103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).
    Tjokroprawiro A
    Acta Med Indones; 2006; 38(3):160-6. PubMed ID: 17119268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peroxisome proliferator-activated receptor gamma agonists as insulin sensitizers: from the discovery to recent progress.
    Cho N; Momose Y
    Curr Top Med Chem; 2008; 8(17):1483-507. PubMed ID: 19075761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease.
    Guan Y; Breyer MD
    Kidney Int; 2001 Jul; 60(1):14-30. PubMed ID: 11422732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PPAR-gamma in ulcerative colitis: a novel target for intervention.
    Bertin B; Dubuquoy L; Colombel JF; Desreumaux P
    Curr Drug Targets; 2013 Nov; 14(12):1501-7. PubMed ID: 23651165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Role of PPARγ, a transcription factor in cardiovascular disease].
    Mukohda M
    Nihon Yakurigaku Zasshi; 2019; 154(2):56-60. PubMed ID: 31406043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peroxisome proliferator-activated receptor gamma (PPARgamma): Is the genomic activity the only answer?
    Luconi M; Cantini G; Serio M
    Steroids; 2010; 75(8-9):585-94. PubMed ID: 19900469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peroxisome proliferator-activated receptor gamma and cardiovascular diseases.
    Takano H; Komuro I
    Circ J; 2009 Feb; 73(2):214-20. PubMed ID: 19129679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PPARgamma agonists and vascular risk factors: potential effects on cardiovascular disease.
    Asnani S; Theuma P; Fonseca VA
    Metab Syndr Relat Disord; 2003 Mar; 1(1):23-32. PubMed ID: 18370623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thiazolidinediones inhibit albumin uptake by proximal tubular cells through a mechanism independent of peroxisome proliferator activated receptor gamma.
    Chana RS; Brunskill NJ
    Am J Nephrol; 2006; 26(1):67-74. PubMed ID: 16508249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Recent trends in PPARgamma agonist development of thiazolidinediones and non-thiazolidinediones].
    Tanaka T
    Nihon Rinsho; 2010 Feb; 68(2):249-55. PubMed ID: 20158092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of PPARgamma activity with pharmaceutical agents: treatment of insulin resistance and atherosclerosis.
    Wang M; Tafuri S
    J Cell Biochem; 2003 May; 89(1):38-47. PubMed ID: 12682906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances on PPARγ Research in the Emerging Era of Precision Medicine.
    Lu P; Zhao Z
    Curr Drug Targets; 2018; 19(6):663-673. PubMed ID: 28641522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PPARγ signaling and emerging opportunities for improved therapeutics.
    Wang S; Dougherty EJ; Danner RL
    Pharmacol Res; 2016 Sep; 111():76-85. PubMed ID: 27268145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxicological consequences of altered peroxisome proliferator-activated receptor gamma (PPARgamma) expression in the liver: insights from models of obesity and type 2 diabetes.
    Boelsterli UA; Bedoucha M
    Biochem Pharmacol; 2002 Jan; 63(1):1-10. PubMed ID: 11754868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) as a Target for Concurrent Management of Diabetes and Obesity-Related Cancer.
    Wang Q; Imam MU; Yida Z; Wang F
    Curr Pharm Des; 2017; 23(25):3677-3688. PubMed ID: 28677503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thiazolidinediones on PPARγ: The Roles in Bone Remodeling.
    Wei W; Wan Y
    PPAR Res; 2011; 2011():867180. PubMed ID: 22135675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual Peroxisome Proliferator-Activated Receptor-alpha/gamma Agonists : In the Treatment of Type 2 Diabetes Mellitus and the Metabolic Syndrome.
    Pershadsingh HA
    Treat Endocrinol; 2006; 5(2):89-99. PubMed ID: 16542049
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.